Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg PCD Pharma Franchise

Brand Name

SITADOL-DM 10/500 Tablet

Composition

Sitagliptin 100mg & Dapagliflozin 10mg & Metformin 500mg

Therapeutic Use

ANTIDIABETICS

Size

10 x 10

Verified Exporter

Verified Seller

Trusted Pharma

Description

SITADOL-DM 10/500 Tablet is listed with a triple antidiabetic composition of Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg. These active ingredients belong to three different classes of glucose-lowering medicines and may be used in the management of type 2 diabetes mellitus when a qualified healthcare professional determines that the combination is appropriate. Confirm the product’s actual label and approved indication before publication.


Sitagliptin is a DPP-4 inhibitor, dapagliflozin is an SGLT2 inhibitor, and metformin is a biguanide. Their complementary mechanisms support blood glucose management alongside appropriate nutrition, physical activity and regular medical monitoring. Treatment suitability depends on kidney function, existing medicines, medical history and the approved prescribing information.

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business enquiries. Organizations researching a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing-source information and relevant quality documentation.


For procurement professionals evaluating a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mgTablets manufacturer and supplier India, essential checks include composition accuracy, product authorization, batch traceability, packaging details, shelf life and applicable regulatory documentation.


2. Key Ingredient 
Composition stated for verification:

Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg


Sitagliptin 100 mg – DPP-4 inhibitor
Sitagliptin helps regulate blood glucose by inhibiting the DPP-4 enzyme, which breaks down incretin hormones. These hormones support glucose-dependent insulin secretion and help regulate glucagon release.
Businesses researching a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg pharmaceutical company India should evaluate the exact formulation, approved product information, regulatory status and quality documentation before procurement.
Dapagliflozin 10 mg – SGLT2 inhibitor
Dapagliflozin reduces glucose reabsorption in the kidneys by inhibiting the SGLT2 transporter. This increases glucose excretion through urine. Kidney function, hydration status and the approved indication are important when evaluating treatment suitability.
Companies searching for a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg medicine manufacturer India should verify the actual manufacturing facility, product-specific permissions, batch-release documentation and applicable quality standards.
Metformin 500 mg – Biguanide
Metformin primarily reduces glucose production in the liver and improves the body’s response to insulin. It is commonly used as part of treatment for type 2 diabetes, subject to clinical assessment and contraindications.
For businesses evaluating a Sitagliptin + Dapagliflozin + Metformin supplier India, important considerations include confirmation of all three strengths, approved labelling, manufacturing-source transparency, storage conditions and documented product quality.


3. Key Benefits
Potential clinical roles of this triple combination, if the exact formulation is approved and prescribed appropriately, include:
1. Multiple glucose-regulating pathways: Combines DPP-4 inhibition, SGLT2 inhibition and metformin’s effects on hepatic glucose production and insulin sensitivity.
2. Type 2 diabetes management: May be considered for eligible patients whose treatment plan requires these active ingredients.
3. Complementary mechanisms: The three medicines influence different physiological pathways involved in glucose regulation.
4. Oral treatment option: Provides an oral formulation option if the product’s dosage form and approved label confirm this.
5. Individualized treatment planning: Allows clinicians to assess whether the combined mechanisms are appropriate for a patient’s specific clinical needs.
6. Ongoing diabetes care: May form part of a broader treatment plan involving nutrition, physical activity, glucose monitoring and regular clinical follow-up.
The combination is not suitable for every patient. Its safety and effectiveness depend on the confirmed formulation, kidney function, concurrent medicines, medical history and clinician assessment. Do not interpret these potential benefits as a guarantee of outcomes.
Pharmaceutical buyers searching for a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg Tablet wholesaler and distributor India should verify distribution eligibility, genuine product documentation, batch traceability and applicable procurement requirements.
Businesses looking for a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg bulk supplier India can request confirmation of available pack sizes, minimum order quantities, shelf life, quality documents and commercial terms.
A Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg pharmaceutical distributor India enquiry should include confirmation of current product availability, applicable licences and authorized distribution arrangements.


4. How Does It Work?
The three active ingredients act through complementary pathways:
– Sitagliptin: Inhibits the DPP-4 enzyme, prolonging incretin activity and supporting glucose-dependent insulin secretion while helping regulate glucagon.
– Dapagliflozin: Inhibits the SGLT2 transporter in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion.
– Metformin: Primarily reduces hepatic glucose production and improves insulin sensitivity, helping the body manage blood glucose more effectively.
Together, these mechanisms target different aspects of glucose regulation. The appropriateness of using all three ingredients in one formulation must be determined from the approved product information and the patient’s clinical requirements.


5. Directions for Use
– Dosage: Take only as prescribed by a qualified doctor. Do not determine the dose independently.
– Administration: Follow the approved product label and the prescriber’s instructions regarding food and administration.
– Regular timing: Take the medicine consistently according to the prescribed schedule.
– Kidney assessment: Kidney function is particularly important because metformin can accumulate in significant renal impairment, while dapagliflozin suitability depends on renal status and the intended indication.
– Missed dose: Follow the approved patient leaflet or consult a pharmacist. Do not take an extra dose without appropriate instructions.
– Illness or surgery: Ask the treating clinician for specific instructions during severe illness, prolonged fasting or before planned surgery, as temporary interruption may be required in certain circumstances.
– Lifestyle management: Continue the recommended diet, physical activity and glucose-monitoring plan.
– Treatment changes: Do not stop, substitute or combine antidiabetic medicines without medical advice.
Important: Confirm that the stated strengths and fixed-dose combination match the actual approved product label. Do not publish a dosing frequency unless it is supported by that label.


6. Possible Side Effects
Potential adverse effects associated with these drug classes include:
– Nausea, diarrhoea, abdominal discomfort or other gastrointestinal symptoms
– Reduced appetite
– Increased urination
– Genital fungal infections or urinary symptoms
– Headache or dizziness
– Dehydration or low blood pressure
– Low blood glucose, particularly when used with insulin or sulfonylureas
– Vitamin B12 deficiency with prolonged metformin use in some patients
Important warning signs
– Possible lactic acidosis: Unusual severe weakness, muscle pain, difficulty breathing, marked drowsiness or abdominal symptoms require urgent medical assessment, particularly in people with risk factors for metformin accumulation.
– Possible ketoacidosis: Nausea, vomiting, abdominal pain, unusual tiredness or difficulty breathing require urgent assessment. Dapagliflozin-associated ketoacidosis can occur even without markedly elevated blood glucose.
– Possible pancreatitis: Persistent severe abdominal pain, especially if it radiates to the back, requires prompt medical evaluation.
– Severe dehydration: Fainting, marked dizziness or inability to maintain fluid intake requires medical attention.
– Serious allergic reaction: Facial or throat swelling, breathing difficulty or a severe skin reaction requires emergency care.
This is not a complete list of adverse effects. Consult the approved prescribing information and a healthcare professional about persistent or concerning symptoms.


7. Safety Information
– Medical supervision: Use only under the guidance of a qualified healthcare professional.
– Product verification: Confirm the exact three-ingredient composition and strengths against the approved product label before prescribing, dispensing or publishing product information.
– Kidney health: Assess renal function before treatment and as clinically indicated. Metformin is contraindicated in severe renal impairment, and the suitability of dapagliflozin depends on renal status and the treatment indication.
– Liver health: Patients with significant liver disease or other risk factors for lactic acidosis require medical assessment before metformin treatment.
– Ketoacidosis: Discuss previous ketoacidosis, prolonged fasting, acute illness, dehydration and planned surgery with the treating clinician.
– Pancreatic history: Report previous pancreatitis or symptoms suggesting acute pancreatitis to the prescribing clinician.
– Fluid balance: Patients taking diuretics, those with low blood pressure and older adults may need additional assessment for dehydration.
– Hypoglycaemia: The risk may increase when the combination is used with insulin or sulfonylureas.
– Pregnancy and breastfeeding: Obtain medical advice before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should review suitable diabetes treatment.
– Drug interactions: Inform the doctor about all prescription medicines, over-the-counter products and supplements.
– Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of reach of children.
This information is educational and does not replace the official prescribing information or individualized medical advice.


8. B2B Pharmaceutical Business Enquiries
CardianCare is associated with cardiac and diabetic healthcare products. Pharmaceutical businesses can contact the company to confirm the current product portfolio, availability and applicable commercial arrangements.
For businesses researching a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg PCD pharma franchise India opportunity, initial enquiries can cover eligible products, territory availability, partner requirements and commercial terms. Confirm that a relevant programme is currently offered before making investment commitments.
A Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg Tablets PCD pharma franchise enquiry should include confirmation of product availability, applicable licensing requirements, promotional policies and distribution eligibility.
Companies exploring a Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg Tablet PCD franchise should verify the current programme, eligible formulations, territory terms and documentation directly with the company.
Businesses investigating Sitagliptin + Dapagliflozin + Metformin third party manufacturing India should first establish whether the proposed business offers such services. Due diligence may include manufacturing permissions, product-specific approvals, applicable GMP compliance, minimum batch quantities, quality agreements and regulatory responsibilities.
A Sitagliptin + Dapagliflozin + Metformin Tablet third party manufacturer India search should involve checking the actual manufacturing facility, product authorization, technical documentation, batch-release procedures and quality systems.
Companies considering Sitagliptin + Dapagliflozin + Metformin contract manufacturing India should confirm the proposed partner’s capabilities, regulatory permissions, formulation specifications, packaging requirements, quality responsibilities and contractual terms.
Contact CardianCare through its official website to enquire about the relevant antidiabetic product, current availability and applicable pharmaceutical business opportunities. Manufacturer, supplier, franchise and manufacturing-service arrangements must be confirmed directly before being represented as available.

For more information about SITADOL-DM 10/500 Tablet (Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg), Click Here

Frequently Asked Questions

The stated ingredients belong to three classes of glucose-lowering medicines that may be used in type 2 diabetes management when clinically appropriate. The exact approved indication must be confirmed from the product label.

The supplied composition is Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg. Verify the strengths and dosage form against the approved pack before publication or dispensing.

Sitagliptin supports incretin-mediated glucose regulation, dapagliflozin increases urinary glucose excretion, and metformin primarily reduces glucose production in the liver while improving insulin sensitivity.

The ingredients act through different pathways involved in glucose regulation. Whether a three-drug combination is suitable depends on the patient's treatment needs, kidney function, tolerability and the approved product information.

Use only as prescribed by a doctor and follow the approved product label. Do not change the dose or administration schedule without medical advice.

Possible effects include gastrointestinal discomfort, increased urination, genital fungal infections, dehydration and headache. Serious warning signs may include lactic acidosis, ketoacidosis, pancreatitis or a severe allergic reaction and require urgent medical assessment.

Patients with significant kidney or liver problems, a history of ketoacidosis or pancreatitis, dehydration, pregnancy considerations or relevant allergies should discuss suitability with their healthcare professional.

Additional diabetes medicines may increase the risk of hypoglycaemia or other adverse effects. A clinician should review the full medication list before adding or changing treatment.

Confirm the composition, strengths, dosage form, product authorization, actual manufacturing source, applicable licences, batch documentation, shelf life, storage requirements and commercial terms.

Contact CardianCare through its official website to confirm current availability and applicable business arrangements. Any franchise, distribution or manufacturing service should be verified directly with the company."

Reviews

There are no reviews yet.

Be the first to review “Sitagliptin 100mg + Dapagliflozin 10mg + Metformin 500mg PCD Pharma Franchise”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line